Date of Presentation
5-2-2024 12:00 AM
College
Rowan-Virtua School of Osteopathic Medicine
Poster Abstract
Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) are hematologic malignancies that originate in the bone marrow and account for approximately 1.3% and 2% of cancer cases, respectively. AML is characterized by an accumulation of myeloblasts, or immature myeloid cells, that have the potential to spread to the peripheral blood. There is an uncontrolled proliferation of plasma cells in the bone marrow in MM. While the current treatment options for both AML and MM show promise in achieving initial remission, it is unfortunately common for patients to experience relapse and develop drug resistance. There is a theory that relapse and resistance could be attributed to the survival of progenitor cells with stem-cell-like properties in the protective niches of the bone marrow. Our research suggests that the plant, soursop, may have potential in combating hematologic cancers by triggering apoptosis and potentially preventing drug resistance and relapse. Soursop, scientifically known as Annona muricata, is a plant that thrives in tropical and subtropical regions. Every component of the plant, including the leaves, fruit, seeds, and bark, exhibit preventative properties against a wide range of diseases. Our study focuses on examining the effectiveness and mode of action of an extract obtained from soursop leaves. We aim to determine its potential in exhibiting anti-cancer properties, specifically against AML and MM cell lines. Our findings reveal that the extract from soursop leaves has the ability to trigger apoptosis and reduce cell viability in HL-60 and MM.1S cells. Through our research, we have discovered the inhibition or downregulation of the JAK/STAT pathway.
Keywords
Acute Myeloid Leukemia, Multiple Myeloma, Soursop, Hematologic Neoplasms, Annona, Apoptosis
Disciplines
Alternative and Complementary Medicine | Cancer Biology | Cell Biology | Hematology | Hemic and Lymphatic Diseases | Medicine and Health Sciences | Neoplasms | Oncology
Document Type
Poster
DOI
10.31986/issn.2689-0690_rdw.stratford_research_day.129_2024
Included in
Alternative and Complementary Medicine Commons, Cancer Biology Commons, Cell Biology Commons, Hematology Commons, Hemic and Lymphatic Diseases Commons, Neoplasms Commons, Oncology Commons
Investigating the Therapeutic Potential of Soursop in Treating Hematologic Malignancies
Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM) are hematologic malignancies that originate in the bone marrow and account for approximately 1.3% and 2% of cancer cases, respectively. AML is characterized by an accumulation of myeloblasts, or immature myeloid cells, that have the potential to spread to the peripheral blood. There is an uncontrolled proliferation of plasma cells in the bone marrow in MM. While the current treatment options for both AML and MM show promise in achieving initial remission, it is unfortunately common for patients to experience relapse and develop drug resistance. There is a theory that relapse and resistance could be attributed to the survival of progenitor cells with stem-cell-like properties in the protective niches of the bone marrow. Our research suggests that the plant, soursop, may have potential in combating hematologic cancers by triggering apoptosis and potentially preventing drug resistance and relapse. Soursop, scientifically known as Annona muricata, is a plant that thrives in tropical and subtropical regions. Every component of the plant, including the leaves, fruit, seeds, and bark, exhibit preventative properties against a wide range of diseases. Our study focuses on examining the effectiveness and mode of action of an extract obtained from soursop leaves. We aim to determine its potential in exhibiting anti-cancer properties, specifically against AML and MM cell lines. Our findings reveal that the extract from soursop leaves has the ability to trigger apoptosis and reduce cell viability in HL-60 and MM.1S cells. Through our research, we have discovered the inhibition or downregulation of the JAK/STAT pathway.